SpotLight-19
Pre-clinical- Indications
- SARS-CoV-2 infection
Company intelligence / Profile preview
ISBRG’s SpotLight platform has demonstrated proof-of-concept for rapid, non-invasive detection of COVID‑19 via a finger scan using light-based technology combined with AI. The company was preparing to conduct clinical trials comparing its device’s accuracy to PCR testing, subject to Health Canada approval as of February 2021. Several published studies support the underlying approach but no large-scale clinical results are yet reported in public sources
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ISBRG Corp..